62 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Tuesday’s Close
RDY Dr. Reddy's Laboratories Ltd $35.7 $5.93B N/A
Article Searches
Dr. Reddy's Reports Positive Top-Line Data on Psoriasis Drug http://www.zacks.com/stock/news/427399/dr-reddys-reports-positive-top-line-data-on-psoriasis-drug?cid=CS-ZC-FT-427399 Jun 10, 2019 - Dr. Reddy's (RDY) reports positive top-line results from the phase IIb study on PPC-06 (formerly referred to as XP23829) in patients with moderate to severe plaque psoriasis.
BioMarin's Vimizim Wins Nod in China for Rare Genetic Malady http://www.zacks.com/stock/news/425808/biomarins-vimizim-wins-nod-in-china-for-rare-genetic-malady?cid=CS-ZC-FT-425808 Jun 06, 2019 - BioMarin's (BMRN) Vimizim gains an NMPA nod in China for addressing patients suffering Morquio A syndrome, an ultra-rare genetic condition.
New Strong Sell Stocks for May 22nd http://www.zacks.com/stock/news/417826/new-strong-sell-stocks-for-may-22nd?cid=CS-ZC-FT-417826 May 22, 2019 - Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Dr. Reddy's Laboratories Ltd (RDY) CEO Gunupati Prasad on Q4 2019 Results - Earnings Call Transcript https://seekingalpha.com/article/4264996-dr-reddys-laboratories-ltd-rdy-ceo-gunupati-prasad-q4-2019-results-earnings-call-transcript?source=feed_tag_india May 17, 2019 - Dr. Reddy's Laboratories Ltd (NYSE:RDY) Q4 2019 Earnings Conference Call May 17, 2019, 08:30 ET Company Participants Amit Agarwal - Director, Finance, FP&A & IR Gunupati Prasad - CEO Saumen Ch
Dr. Reddy's (RDY) Earnings Rise in Q4, Revenues Beat http://www.zacks.com/stock/news/415513/dr-reddys-rdy-earnings-rise-in-q4-revenues-beat?cid=CS-ZC-FT-415513 May 17, 2019 - Dr. Reddy's earnings and sales increase year over year in the fourth quarter of fiscal 2019.
Supernus' ADHD Candidate Positive in 4th Phase III Study http://www.zacks.com/stock/news/368648/supernus-adhd-candidate-positive-in-4th-phase-iii-study?cid=CS-ZC-FT-368648 Apr 01, 2019 - Supernus (SUPN) releases top-line results from the fourth phase III study on SPN-812 for the treatment of attention deficit hyperactivity disorder.
Falling Earnings Estimates Signal Weakness Ahead for Mylan (MYL) http://www.zacks.com/stock/news/365966/falling-earnings-estimates-signal-weakness-ahead-for-mylan-myl?cid=CS-ZC-FT-365966 Mar 28, 2019 - Mylan (MYL) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
Top Ranked Momentum Stocks to Buy for March 20th http://www.zacks.com/commentary/362180/top-ranked-momentum-stocks-to-buy-for-march-20th?cid=CS-ZC-FT-362180 Mar 20, 2019 - Top Ranked Momentum Stocks to Buy for March 20th
Dr. Reddy's Laboratories Limited (RDY) Q3 2019 Results - Earnings Call Transcript https://seekingalpha.com/article/4237615-dr-reddys-laboratories-limited-rdy-q3-2019-results-earnings-call-transcript?source=feed_tag_india Feb 01, 2019 -
Akorn (AKRX) Gets FDA Warning Letter for Illinois Facility http://www.zacks.com/stock/news/346828/akorn-akrx-gets-fda-warning-letter-for-illinois-facility?cid=CS-ZC-FT-346828 Jan 10, 2019 - Akorn, Inc. (AKRX) suffers a setback with the FDA handing over a warning letter post an inspection of its Illinois manufacturing facility in April and May of 2018.

Pages: 1234567

Page 1>